AstraZeneca
AZN
1,224 hedge funds and large institutions have $34.7B invested in AstraZeneca in 2025 Q2 according to their latest regulatory filings, with 95 funds opening new positions, 458 increasing their positions, 439 reducing their positions, and 113 closing their positions.
130% more call options, than puts
Call options by funds: $596M | Put options by funds: $259M
4% more repeat investments, than reductions
Existing positions increased: 458 | Existing positions reduced: 439
0.3% less ownership
Funds ownership: 16.3% → 16% (-0.3%)
2% less funds holding
Funds holding: 1,252 → 1,224 (-28)
16% less first-time investments, than exits
New positions opened: 95 | Existing positions closed: 113
25% less capital inflows, than outflows
Capital inflows: $1.98B | Capital outflows: $2.64B
50% less funds holding in top 10
Funds holding in top 10: 22 → 11 (-11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fayez Sarofim & Co
Houston,
Texas
|
+$166M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$137M |
| 3 |
Jennison Associates
New York
|
+$112M |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
+$104M |
| 5 |
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
+$97.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$360M |
| 2 |
Morgan Stanley
New York
|
-$249M |
| 3 |
Soros Fund Management
New York
|
-$202M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$171M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$123M |
AZN Hedge Fund Activity: Q2 2025 in Review
1,224 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2025, worth a combined $34.7B — down 7% from $37.3B a quarter earlier.
Sellers outnumbered buyers: 113 funds closed out of AZN and 95 opened new positions — a net loss of 18 holders — while 439 trimmed existing stakes and 458 added.
The largest buyer was Fayez Sarofim & Co, adding an estimated $166M. The largest seller was T. Rowe Price Associates, cutting an estimated $360M.
- 1,224 institutional investors held AstraZeneca (AZN) as of Q2 2025, down from 1,252 in Q1 2025.
- Funds reported $34.7B of AstraZeneca stock for Q2 2025, down 7% quarter-over-quarter.
- 95 funds opened new AstraZeneca positions in Q2 2025 and 113 closed out, a net change of -18 holders.
- The largest AstraZeneca buyer in Q2 2025 was Fayez Sarofim & Co, an estimated $166M added.
- The largest AstraZeneca seller in Q2 2025 was T. Rowe Price Associates, an estimated $360M sold.
Based on aggregated 13F filings for Q2 2025.